0P5I Stock Overview
Mauna Kea Technologies SA develops and markets medical devices in Europe and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Mauna Kea Technologies SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.39 |
| 52 Week High | €0.76 |
| 52 Week Low | €0.39 |
| Beta | 1.38 |
| 1 Month Change | -6.94% |
| 3 Month Change | -13.94% |
| 1 Year Change | -28.88% |
| 3 Year Change | -72.29% |
| 5 Year Change | -79.03% |
| Change since IPO | -96.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0P5I | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -5.0% | -1.1% | 2.2% |
| 1Y | -28.9% | -11.3% | 0.9% |
Price Volatility
| 0P5I volatility | |
|---|---|
| 0P5I Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Volatility Over Time: Insufficient data to determine 0P5I's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 67 | Sacha Loiseau | www.maunakeatech.com |
Mauna Kea Technologies SA develops and markets medical devices in Europe and internationally. The company offers range of medical devices, which includes gastroenterology, pulmonology, urology, and drug development. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform which enables physicians to monitor progression of disease over time, assess point-in-time reactions, classify indeterminate areas, and guide surgical interventions.
Mauna Kea Technologies SA Fundamentals Summary
| 0P5I fundamental statistics | |
|---|---|
| Market cap | €23.36m |
| Earnings (TTM) | -€2.17m |
| Revenue (TTM) | €11.54m |
2.0x
P/S Ratio-10.8x
P/E RatioIs 0P5I overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0P5I income statement (TTM) | |
|---|---|
| Revenue | €11.54m |
| Cost of Revenue | €1.89m |
| Gross Profit | €9.66m |
| Other Expenses | €11.83m |
| Earnings | -€2.17m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Sep 26, 2024
| Earnings per share (EPS) | -0.035 |
| Gross Margin | 83.66% |
| Net Profit Margin | -18.79% |
| Debt/Equity Ratio | -176.5% |
How did 0P5I perform over the long term?
See historical performance and comparison